Health Care Standout Celgene Corporation (CELG) Making Gains Today

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Celgene Corporation ( CELG) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Celgene Corporation rose $2.18 (1.8%) to $122.99 on average volume. Throughout the day, 3.2 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.3 million shares. The stock ranged in a price between $121.61-$123.80 after having opened the day at $121.75 as compared to the previous trading day's close of $120.81. Other companies within the Health Care sector that increased today were: ACADIA Pharmaceuticals ( ACAD), up 64.4%, Redhill Biopharma ( RDHL), up 17%, Biolase ( BIOL), up 13.3%, and Coronado Biosciences ( CNDO), up 11.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $48.83 billion and is part of the drugs industry. The company has a P/E ratio of 35.3, above the S&P 500 P/E ratio of 17.7. Shares are up 48.6% year to date as of the close of trading on Wednesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Durata Therapeutics ( DRTX), down 15.6%, Genvec ( GNVC), down 13%, Synergy Pharmaceuticals ( SGYP), down 11.5%, and Integra LifeSciences Holdings ( IART), down 11.1%, were all laggards within the health care sector with Mettler-Toledo International ( MTD) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Three Stocks That Have My Attention

Three Stocks That Have My Attention

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices